265 related articles for article (PubMed ID: 37258038)
1. Cell surface marker-based capture of neoantigen-reactive CD8
Chatani PD; Lowery FJ; Parikh NB; Hitscherich KJ; Yossef R; Hill V; Gartner JJ; Paria B; Florentin M; Ray S; Bera A; Parkhust M; Robbins P; Krishna S; Rosenberg SA
J Immunother Cancer; 2023 May; 11(5):. PubMed ID: 37258038
[TBL] [Abstract][Full Text] [Related]
2. Molecular signatures of antitumor neoantigen-reactive T cells from metastatic human cancers.
Lowery FJ; Krishna S; Yossef R; Parikh NB; Chatani PD; Zacharakis N; Parkhurst MR; Levin N; Sindiri S; Sachs A; Hitscherich KJ; Yu Z; Vale NR; Lu YC; Zheng Z; Jia L; Gartner JJ; Hill VK; Copeland AR; Nah SK; Masi RV; Gasmi B; Kivitz S; Paria BC; Florentin M; Kim SP; Hanada KI; Li YF; Ngo LT; Ray S; Shindorf ML; Levi ST; Shepherd R; Toy C; Parikh AY; Prickett TD; Kelly MC; Beyer R; Goff SL; Yang JC; Robbins PF; Rosenberg SA
Science; 2022 Feb; 375(6583):877-884. PubMed ID: 35113651
[TBL] [Abstract][Full Text] [Related]
3. Phenotypic signatures of circulating neoantigen-reactive CD8
Yossef R; Krishna S; Sindiri S; Lowery FJ; Copeland AR; Gartner JJ; Parkhurst MR; Parikh NB; Hitscherich KJ; Levi ST; Chatani PD; Zacharakis N; Levin N; Vale NR; Nah SK; Dinerman A; Hill VK; Ray S; Bera A; Levy L; Jia L; Kelly MC; Goff SL; Robbins PF; Rosenberg SA
Cancer Cell; 2023 Dec; 41(12):2154-2165.e5. PubMed ID: 38039963
[TBL] [Abstract][Full Text] [Related]
4. Enhanced detection of neoantigen-reactive T cells targeting unique and shared oncogenes for personalized cancer immunotherapy.
Yossef R; Tran E; Deniger DC; Gros A; Pasetto A; Parkhurst MR; Gartner JJ; Prickett TD; Cafri G; Robbins PF; Rosenberg SA
JCI Insight; 2018 Oct; 3(19):. PubMed ID: 30282837
[TBL] [Abstract][Full Text] [Related]
5. Isolation of T-Cell Receptors Specifically Reactive with Mutated Tumor-Associated Antigens from Tumor-Infiltrating Lymphocytes Based on CD137 Expression.
Parkhurst M; Gros A; Pasetto A; Prickett T; Crystal JS; Robbins P; Rosenberg SA
Clin Cancer Res; 2017 May; 23(10):2491-2505. PubMed ID: 27827318
[No Abstract] [Full Text] [Related]
6. Reprogramming of Tumor-reactive Tumor-infiltrating Lymphocytes to Human-induced Pluripotent Stem Cells.
Islam SMR; Maeda T; Tamaoki N; Good ML; Kishton RJ; Paria BC; Yu Z; Bosch-Marce M; Bedanova NM; Liu C; Kruhlak MJ; Restifo NP; Vizcardo R
Cancer Res Commun; 2023 May; 3(5):917-932. PubMed ID: 37377887
[TBL] [Abstract][Full Text] [Related]
7. A phenotypic signature that identifies neoantigen-reactive T cells in fresh human lung cancers.
Hanada KI; Zhao C; Gil-Hoyos R; Gartner JJ; Chow-Parmer C; Lowery FJ; Krishna S; Prickett TD; Kivitz S; Parkhurst MR; Wong N; Rae Z; Kelly MC; Goff SL; Robbins PF; Rosenberg SA; Yang JC
Cancer Cell; 2022 May; 40(5):479-493.e6. PubMed ID: 35452604
[TBL] [Abstract][Full Text] [Related]
8. Generation of neoantigen-specific T cells for adoptive cell transfer for treating head and neck squamous cell carcinoma.
Wei T; Leisegang M; Xia M; Kiyotani K; Li N; Zeng C; Deng C; Jiang J; Harada M; Agrawal N; Li L; Qi H; Nakamura Y; Ren L
Oncoimmunology; 2021 May; 10(1):1929726. PubMed ID: 34104546
[TBL] [Abstract][Full Text] [Related]
9. Antigen/HLA-agnostic strategies for Characterizing Tumor-responsive T cell receptors in PDAC patients via single-cell sequencing and autologous organoid application.
Wang X; Dai Z; Lin X; Zou X; Wang R; Tasiheng Y; Yan Y; Ma M; Chen Y; Cheng H; Liu C; Yu X
Cancer Lett; 2024 Apr; 588():216741. PubMed ID: 38395378
[TBL] [Abstract][Full Text] [Related]
10. Tumor-reactive CD8+ T cells in metastatic gastrointestinal cancer refractory to chemotherapy.
Turcotte S; Gros A; Tran E; Lee CC; Wunderlich JR; Robbins PF; Rosenberg SA
Clin Cancer Res; 2014 Jan; 20(2):331-43. PubMed ID: 24218514
[TBL] [Abstract][Full Text] [Related]
11. Isolation of T cell receptor specifically reactive with autologous tumour cells from tumour-infiltrating lymphocytes and construction of T cell receptor engineered T cells for esophageal squamous cell carcinoma.
Tan Q; Zhang C; Yang W; Liu Y; Heyilimu P; Feng D; Xing L; Ke Y; Lu Z
J Immunother Cancer; 2019 Aug; 7(1):232. PubMed ID: 31462302
[TBL] [Abstract][Full Text] [Related]
12. Neoantigen-specific CD4
Hall MS; Teer JK; Yu X; Branthoover H; Snedal S; Rodriguez-Valentin M; Nagle L; Scott E; Schachner B; Innamarato P; Hall AM; Blauvelt J; Rich CJ; Richards AD; Ceccarelli J; Langer TJ; Yoder SJ; Beatty MS; Cox CA; Messina JL; Abate-Daga D; Mule JJ; Mullinax JE; Sarnaik AA; Pilon-Thomas S
J Immunother Cancer; 2023 Oct; 11(10):. PubMed ID: 37802604
[TBL] [Abstract][Full Text] [Related]
13. Single-cell sequencing on CD8
Komuro H; Shinohara S; Fukushima Y; Demachi-Okamura A; Muraoka D; Masago K; Matsui T; Sugita Y; Takahashi Y; Nishida R; Takashima C; Ohki T; Shigematsu Y; Watanabe F; Adachi K; Fukuyama T; Hamana H; Kishi H; Miura D; Tanaka Y; Onoue K; Onoguchi K; Yamashita Y; Stratford R; Clancy T; Yamaguchi R; Kuroda H; Doi K; Iwata H; Matsushita H
J Immunother Cancer; 2023 Aug; 11(8):. PubMed ID: 37544663
[TBL] [Abstract][Full Text] [Related]
14. CD103 and CD39 coexpression identifies neoantigen-specific cytotoxic T cells in colorectal cancers with low mutation burden.
van den Bulk J; van der Ploeg M; Ijsselsteijn ME; Ruano D; van der Breggen R; Duhen R; Peeters KCMJ; Fariña-Sarasqueta A; Verdegaal EME; van der Burg SH; Duhen T; de Miranda NFCC
J Immunother Cancer; 2023 Feb; 11(2):. PubMed ID: 36792124
[TBL] [Abstract][Full Text] [Related]
15. Neoantigen-specific immunity in low mutation burden colorectal cancers of the consensus molecular subtype 4.
van den Bulk J; Verdegaal EME; Ruano D; Ijsselsteijn ME; Visser M; van der Breggen R; Duhen T; van der Ploeg M; de Vries NL; Oosting J; Peeters KCMJ; Weinberg AD; Farina-Sarasqueta A; van der Burg SH; de Miranda NFCC
Genome Med; 2019 Dec; 11(1):87. PubMed ID: 31888734
[TBL] [Abstract][Full Text] [Related]
16. Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients.
Gros A; Parkhurst MR; Tran E; Pasetto A; Robbins PF; Ilyas S; Prickett TD; Gartner JJ; Crystal JS; Roberts IM; Trebska-McGowan K; Wunderlich JR; Yang JC; Rosenberg SA
Nat Med; 2016 Apr; 22(4):433-8. PubMed ID: 26901407
[TBL] [Abstract][Full Text] [Related]
17. Tumor- and Neoantigen-Reactive T-cell Receptors Can Be Identified Based on Their Frequency in Fresh Tumor.
Pasetto A; Gros A; Robbins PF; Deniger DC; Prickett TD; Matus-Nicodemos R; Douek DC; Howie B; Robins H; Parkhurst MR; Gartner J; Trebska-McGowan K; Crystal JS; Rosenberg SA
Cancer Immunol Res; 2016 Sep; 4(9):734-43. PubMed ID: 27354337
[TBL] [Abstract][Full Text] [Related]
18. Direct identification of neoantigen-specific TCRs from tumor specimens by high-throughput single-cell sequencing.
Lu YC; Zheng Z; Lowery FJ; Gartner JJ; Prickett TD; Robbins PF; Rosenberg SA
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34321276
[TBL] [Abstract][Full Text] [Related]
19. Immunological ignorance is an enabling feature of the oligo-clonal T cell response to melanoma neoantigens.
Linette GP; Becker-Hapak M; Skidmore ZL; Baroja ML; Xu C; Hundal J; Spencer DH; Fu W; Cummins C; Robnett M; Kaabinejadian S; Hildebrand WH; Magrini V; Demeter R; Krupnick AS; Griffith OL; Griffith M; Mardis ER; Carreno BM
Proc Natl Acad Sci U S A; 2019 Nov; 116(47):23662-23670. PubMed ID: 31685621
[TBL] [Abstract][Full Text] [Related]
20. Defined tumor antigen-specific T cells potentiate personalized TCR-T cell therapy and prediction of immunotherapy response.
He J; Xiong X; Yang H; Li D; Liu X; Li S; Liao S; Chen S; Wen X; Yu K; Fu L; Dong X; Zhu K; Xia X; Kang T; Bian C; Li X; Liu H; Ding P; Zhang X; Liu Z; Li W; Zuo Z; Zhou P
Cell Res; 2022 Jun; 32(6):530-542. PubMed ID: 35165422
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
